Your Source for Venture Capital and Private Equity Financings

VC-funded Company:

Recida Therapeutics
70 Willow Rd., Suite 200
Menlo Park, CA 94025
Phone: 650-325-5156
http://www.recidatherapeutics.com/

Recida Therapeutics, Inc., a biopharmaceutical company focused on the development of novel therapeutics for serious antibiotic-resistant infections. Recida's lead program, RC-01, is a novel, IND-stage LpxC inhibitor for the treatment of multidrug-resistant gram-negative infections. Recida has licensed development and commercialization rights to RC-01 from FUJIFILM Toyama Chemical Co. Ltd. for all territories outside Japan. Recida intends to a submit an Investigational New Drug application (IND) for RC-01 to the U.S. Food and Drug Administration (FDA) in the first quarter of 2019.

Key Contact
Name
James Yigong Ge
Title
CEO
E-Mail
Funding Events

Date
Amount
Type
Investors
Valuation
02/06/19 $8,500,000 Series A Frazier Healthcare
undisclosed